UNI-MB - logo
UMNIK - logo
 
E-viri
  • Inferior Access to Allogene...
    Paulson, Kristjan; Brazauskas, Ruta; Khera, Nandita; He, Naya; Majhail, Navneet; Akpek, Gorgun; Aljurf, Mahmoud; Buchbinder, David; Burns, Linda; Beattie, Sara; Freytes, Cesar; Garcia, Anne; Gajewski, James; Hahn, Theresa; Knight, Jennifer; LeMaistre, Charles; Lazarus, Hillard; Szwajcer, David; Seftel, Matthew; Wirk, Baldeep; Wood, William; Saber, Wael

    Biology of blood and marrow transplantation, October 2019, 2019-10-00, 20191001, Letnik: 25, Številka: 10
    Journal Article

    •Patients with acute myelogenous leukemia, acute lymphocytic leukemia, and myelodysplastic syndrome from areas with more poverty had lower rates of allogeneic hematopoietic cell transplantation (alloHCT).•These results were confirmed by multiple sensitivity analyses.•Family size, minority status, and rural residence were less important than poverty rate.•Some 2500 additional patients per year would undergo alloHCT if poverty were not a barrier. Allogeneic hematopoietic cell transplantation (alloHCT) is offered in a limited number of medical centers and is associated with significant direct and indirect costs. The degree to which social and geographic barriers reduce access to alloHCT is unknown. Data from the Surveillance, Epidemiology and End Results Program (SEER) and the Center for International Blood and Marrow Transplant Research (CIBMTR) were integrated to determine the rate of unrelated donor (URD) alloHCT for acute myelogenous leukemia (AML), acute lymphoblastic leukemia (ALL), and myelodysplastic syndrome (MDS) performed between 2000 and 2010 in the 612 counties covered by SEER. The total incidence of AML, ALL, and MDS was determined using SEER, and the number of alloHCTs performed in the same time period and geographic area were determined using the CIBMTR database. We then determined which sociodemographic attributes influenced the rate of alloHCT (rural/urban status, median family size, percentage of residents below the poverty line, and percentage of minority race). In the entire cohort, higher levels of poverty were associated with lower rates of alloHCT (estimated rate ratio ERR, .86 for a 10% increase in the percentage of the population below the poverty line; P < .01), whereas rural location was not (ERR, .87; P = .11). Thus, patients from areas with higher poverty rates diagnosed with ALL, AML, and MDS are less likely patients from wealthier counties to undergo URD alloHCT. There is need to better understand the reasons for this disparity and to encourage policy and advocacy efforts to improve access to medical care for all.